Combating increased antifungal drug resistance in Cryptococcus,what should we do in the future?  

作　　者：Hengyu Deng Jialin Song Yemei Huang Chen Yang Xuelei Zang Yangyu Zhou Hongli Li Bin Dai Xinying Xue 

机构地区：[1]Affiliated Hospital of Weifang Medical University,School of Clinical Medicine,Weifang Medical University,Weifang 261053,China [2]Department of Respiratory and Critical Care,Beijing Shijtan Hospital,Capital Medical University,Peking University Ninth School of Clinical Medicine,Beijing 100089,China [3]Department of Laboratory Medicine,the First Medical Centre,Chinese PLA General Hospital,Beijing 100853,China

出　　处：《Acta Biochimica et Biophysica Sinica》2023年第4期540-547,共8页生物化学与生物物理学报（英文版）

基　　金：the National Key Research and Development Program(No.2021YFC2302100);the National Key Research and Development Program(No.2020YFC2005404);the Beijing Key Clinical Specialty Project(No.2020ZDZK1);the National Capacity Building Project for Multidisciplinary Diagnosis and Treatment of Major Diseases(No.2019YLFW);the Capital Health Development Scientific Research Unit Matching Fund(No.2020-2Z-2086);the“Sailing”Plan for Clinical Technology Innovation Project in Beijing(No.XMLX202115).

摘　　要：Few therapeutic drugs and increased drug resistance have aggravated the current treatment difficulties of Cryptococcus in recent years.To better understand the antifungal drug resistance mechanism and treatment strategy of cryptococcosis.In this review,by combining the fundamental features of Cryptococcus reproduction leading to changes in its genome,we review recent research into the mechanism of four current anti-cryptococcal agents,coupled with new therapeutic strategies and the application of advanced technologies WGS and CRISPR-Cas9 in this field,hoping to provide a broad idea for the future clinical therapy of cryptococcosis.

关 键 词：CRYPTOCOCCUS anti-cryptococcal agent drug resistance mechanism drug target 

分 类 号：R978.5[医药卫生—药品]